Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Fish and Richardson
McKesson
Teva
QuintilesIMS
McKinsey
Chinese Patent Office
UBS
Citi

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DIFICID

« Back to Dashboard

Clinical Trials for Dificid

Trial ID Title Status Sponsor Phase Summary
NCT01552668 Fidaxomicin to Prevent Clostridium Difficile Colonization Withdrawn Centers for Disease Control and Prevention Phase 4 The purpose of this research study is to evaluate the effectiveness of an antibiotic called fidaxomicin in preventing C. difficile infection.
NCT01552668 Fidaxomicin to Prevent Clostridium Difficile Colonization Withdrawn Washington University School of Medicine Phase 4 The purpose of this research study is to evaluate the effectiveness of an antibiotic called fidaxomicin in preventing C. difficile infection.
NCT01691248 Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) Completed Optimer Pharmaceuticals LLC Phase 3 The objective of this study is to demonstrate the efficacy and safety of Fidaxomicin versus placebo for prophylaxis against Clostridium difficile-Associated Diarrhea (CDAD) in adult participants undergoing hematopoietic stem cell transplantation (HSCT). The primary hypothesis is that Fidaxomicin is superior to placebo in preventing CDAD in participants undergoing HSCT.
NCT01813448 A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects Completed Cubist Pharmaceuticals LLC Phase 1 The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single and multiple ascending doses of fidaxomicin in healthy subjects. This study will also compare the safety, tolerability and PK of single and multiple doses of fidaxomicin in healthy Japanese and Caucasian subjects.
NCT01813448 A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects Completed Astellas Pharma Global Development, Inc. Phase 1 The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single and multiple ascending doses of fidaxomicin in healthy subjects. This study will also compare the safety, tolerability and PK of single and multiple doses of fidaxomicin in healthy Japanese and Caucasian subjects.
NCT02057198 Impact of Oral Antibiotic Treatment on C. Difficile Recruiting Duke University Phase 4 The overall aim is to characterize and to compare the extent and quantity of C. difficile stool shedding, perianal colonization and environmental contamination in patients who received oral fidaxomicin, oral metronidazole, or oral vancomycin. This is a prospective, randomized, microbiologic and molecular, study of environmental contamination from patients with proven C. difficile associated diarrhea (CDAD).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Dificid

Condition Name

Condition Name for Dificid
Intervention Trials
Clostridium Difficile Infection 3
Clostridium Difficile-associated Diarrhea (CDAD) 2
Clostridium Difficile 2
Diarrhea 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dificid
Intervention Trials
Diarrhea 3
Infection 3
Communicable Diseases 2
Spinal Cord Injuries 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dificid

Trials by Country

Trials by Country for Dificid
Location Trials
United States 21
Poland 5
Romania 4
Canada 4
Belgium 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dificid
Location Trials
North Carolina 2
California 2
Missouri 2
Illinois 1
Indiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dificid

Clinical Trial Phase

Clinical Trial Phase for Dificid
Clinical Trial Phase Trials
Phase 4 4
Phase 3 3
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dificid
Clinical Trial Phase Trials
Recruiting 4
Completed 3
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dificid

Sponsor Name

Sponsor Name for Dificid
Sponsor Trials
Cubist Pharmaceuticals LLC 2
Merck Sharp & Dohme Corp. 2
Astellas Pharma S.A.S. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dificid
Sponsor Trials
Industry 9
Other 4
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Covington
Deloitte
Farmers Insurance
Queensland Health
Medtronic
US Department of Justice
QuintilesIMS
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.